You can read the complete article at the publisher's website
Molecular Cancer Therapeutics. Search for Ganetespib and scroll down to find the article. Click on Full PDF to see the article.
Sentiment: Strong Buy
btw: Why was there no press release about this ? That seems really strange.
There is also no press release when they file patents.
The company clearly increases its absolute value without much of a PPS move.
Makes you wonder if insiders and/or investors such as Caxton and Kovner are planing on increasing their SNTA holdings even more...and as such would rather see a static price ?! ...for now.
Obviously once the "final plan" hits the wire, there will be nothing static about this stock.
I am sticking with the insiders.
My guess is because it's a pre-clinical study.
IDK....was wondering the same thing
Thanks for pointing this out.
"A significant finding of this study was that ganetespib could overcome both intrinsic and acquired
vemurafenib resistance in melanoma lines."
"ganetespib retained full single-agent potency against vemurafenib-resistant cells and, indeed, they remained more sensitive to ganetespib compared to the parental line to vemurafenib"